When to Order Imaging for Staging and Follow-up of Primary Liver Cancer: ACR Appropriateness Decoded

When to Order Imaging for Staging and Follow-up of Primary Liver Cancer: ACR Appropriateness Decoded

A 65-year-old patient with a history of cirrhosis presents for a routine screening ultrasound, which reveals a new 2.5 cm liver observation. The next step is characterization and staging, but the choice between multiphase Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) can be complex, involving considerations of contrast allergies, renal function, and institutional expertise. For patients already undergoing treatment or surveillance, determining the optimal follow-up modality and frequency is equally critical. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria for staging and follow-up of primary liver cancer, providing a clear framework for ordering the right imaging study at the right time.

What Does ACR Staging and Follow-up of Primary Liver Cancer Cover?

These ACR guidelines focus on imaging for patients with suspected or confirmed primary liver cancer, most commonly Hepatocellular Carcinoma (HCC). The criteria address several distinct clinical phases: screening for at-risk populations (e.g., patients with cirrhosis), initial staging of a newly diagnosed cancer, active surveillance of indeterminate liver observations, and post-treatment evaluation for both response assessment and long-term surveillance for recurrence. The recommendations are tailored to help clinicians select the most effective modality to characterize lesions, define the extent of disease, and monitor treatment efficacy. These criteria do not apply to the initial workup of an incidental liver lesion in a low-risk patient without underlying liver disease, nor do they cover the staging of metastatic disease to the liver from a non-hepatic primary cancer.

What Imaging Should I Order for Staging and Follow-up of Primary Liver Cancer? Recommendations by Clinical Scenario

Imaging selection for primary liver cancer is highly dependent on the clinical context. The ACR provides specific guidance for each stage of patient management, from initial screening to post-treatment follow-up.

For screening in an adult with risk factors for primary liver cancer, an abdominal ultrasound is rated Usually appropriate. It is a non-invasive, cost-effective first-line tool for detecting liver nodules. If a suspicious observation is found, cross-sectional imaging is required for definitive characterization. In this screening context, both MRI of the abdomen without and with IV contrast and multiphase CT of the abdomen with IV contrast are considered May be appropriate, typically as second-line or problem-solving tools.

For initial staging of primary liver cancer, both MRI of the abdomen without and with IV contrast and multiphase CT of the abdomen with IV contrast are rated Usually appropriate. These modalities are essential for characterizing the primary tumor according to systems like LI-RADS (Liver Imaging Reporting and Data System), assessing for vascular invasion, and detecting intrahepatic metastases, all of which are critical for determining treatment eligibility (e.g., resection, transplant, or locoregional therapy). For evaluating extrahepatic disease, studies like a whole-body bone scan or a CT of the chest may be appropriate depending on the clinical suspicion for metastases.

For patients with liver observations under active surveillance, the recommendations mirror those for initial staging. Both MRI of the abdomen without and with IV contrast and multiphase CT of the abdomen with IV contrast are Usually appropriate. These studies allow for precise measurement and characterization of indeterminate nodules over time to detect growth or the development of features diagnostic of HCC.

Following locoregional treatment or neoadjuvant chemotherapy, imaging is crucial for assessing response. For this posttreatment evaluation, MRI of the abdomen without and with IV contrast, multiphase CT of the abdomen with IV contrast, and CT of the abdomen without and with IV contrast are all rated Usually appropriate. These studies are used to evaluate the treatment zone for residual or recurrent viable tumor, which typically appears as areas of arterial phase hyperenhancement.

Finally, for routine surveillance in a treated patient, MRI of the abdomen without and with IV contrast and multiphase CT of the abdomen with IV contrast are again rated Usually appropriate. These modalities are the standard of care for long-term monitoring to detect local recurrence or the development of new tumors elsewhere in the liver.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Primary Liver Cancer Imaging: Radiation Dose Tradeoffs

While primary liver cancer is far more common in adults, pediatric liver tumors like hepatoblastoma require careful imaging considerations. The principle of ALARA (As Low As Reasonably Achievable) is paramount in pediatric imaging due to the increased radiosensitivity of developing tissues and the longer lifespan over which the risks of radiation-induced malignancy can manifest. For this reason, non-ionizing modalities like ultrasound and MRI are strongly preferred whenever they can provide the necessary diagnostic information. The ACR guidelines reflect this by providing specific pediatric relative radiation level (RRL) estimates, which are often in a higher tier than the adult equivalent for the same CT scan due to the smaller body habitus and increased organ sensitivity. When CT is unavoidable for pediatric staging or follow-up, protocols must be optimized to use the lowest possible radiation dose, a process that often involves collaboration between radiologists and medical physicists to ensure images are diagnostic while minimizing risk.

Imaging Protocol Details for Staging and Follow-up of Primary Liver Cancer

Once you’ve decided on the right study, the specific imaging protocol is critical for accurate diagnosis and staging. Multiphase contrast-enhanced studies are the standard for evaluating HCC, requiring precise timing of arterial, portal venous, and delayed phases to capture the characteristic enhancement patterns. Our protocol guides cover technique, contrast, and reading principles for the studies recommended above:

• CT Chest/Abdomen/Pelvis with IV Contrast
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines and radiation safety can be streamlined with the right digital tools. GigHz offers several resources designed to support clinical decision-making for physicians and trainees.

The ACR Appropriateness Criteria Lookup provides a searchable interface to the complete ACR guidelines, allowing you to quickly find evidence-based recommendations for hundreds of clinical scenarios beyond primary liver cancer.

For detailed procedural information, the Imaging Protocol Library offers in-depth guides on how specific studies are performed, including patient prep, contrast administration, and key imaging sequences for both CT and MRI.

To help with patient communication and safety, the Radiation Dose Calculator allows you to estimate and track cumulative radiation exposure from various imaging studies, facilitating informed discussions about the risks and benefits of imaging.

What is the first-line imaging for screening for primary liver cancer in a high-risk patient?

According to the ACR, a standard transabdominal ultrasound of the abdomen is the “Usually appropriate” first-line modality for screening in high-risk patients, such as those with cirrhosis. It is non-invasive, widely available, and does not use ionizing radiation.

For staging HCC, is multiphase CT or MRI better?

Both multiphase CT with IV contrast and MRI of the abdomen without and with IV contrast are rated “Usually appropriate” for staging primary liver cancer. The choice often depends on institutional preference, patient factors (e.g., renal function, contrast allergies, presence of an implanted device), and the need for specific tissue characterization. MRI is generally considered to have slightly higher sensitivity for detecting small lesions and characterizing tumor features, but multiphase CT is often faster and more accessible.

Why is a non-contrast CT of the abdomen “Usually not appropriate” for staging or surveillance?

The diagnosis and characterization of Hepatocellular Carcinoma (HCC) rely heavily on its specific vascular enhancement pattern. A non-contrast CT cannot demonstrate the hallmark arterial phase hyperenhancement and subsequent portal venous or delayed phase “washout” that are critical for a definitive diagnosis under the LI-RADS criteria. Therefore, a multiphase study with IV contrast is required.

What is the role of PET/CT in managing primary liver cancer?

In the ACR guidelines for staging and follow-up, FDG-PET/CT is rated “Usually not appropriate.” While PET/CT is crucial for staging many other malignancies, its utility in HCC is limited because HCC tumors can have variable FDG avidity. Some well-differentiated tumors do not take up a significant amount of the FDG tracer, leading to false-negative results. It may have a role in specific cases, such as evaluating for extrahepatic metastatic disease in patients being considered for transplant, but it is not a routine part of initial staging or follow-up.

How often should surveillance imaging be performed after treatment for HCC?

The optimal frequency of surveillance imaging after definitive treatment is not specified in this ACR document but is addressed by other societal guidelines (e.g., AASLD). Typically, surveillance with multiphase CT or MRI is performed every 3 to 6 months for the first two years, as this is the period of highest risk for recurrence. The interval may be extended after that based on the individual patient’s risk profile.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026